Showing results (1-10 of 458) with videos related to

Sort By:
Pageof 46
The Lancet. Rheumatology|June 14, 2022
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platformBrian MacKenna, Nicholas A Kennedy, Amir Mehrkar, et al.
The Lancet. Rheumatology|April 5, 2021
The role of antirheumatics in patients with COVID-19Christoffer B Nissen, Savino Sciascia, Danieli de Andrade, et al.
The Lancet. Rheumatology|May 4, 2021
SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional studyDavid Saadoun, Matheus Vieira, Mathieu Vautier, et al.
The Lancet. Rheumatology|April 14, 2020
Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trialAthimalaipet V Ramanan, Andrew D Dick, Catherine Guly, et al.
The Lancet. Rheumatology|November 22, 2021
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort CollaborativeKathleen M Andersen, Benjamin A Bates, Emaan S Rashidi, et al.
The Lancet. Rheumatology|August 31, 2022
Shared genetic susceptibility between trigger finger and carpal tunnel syndrome: a genome-wide association studyBenjamin Patel, Sam O Kleeman, Drew Neavin, et al.
The Lancet. Rheumatology|October 4, 2021
The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort studyJagtar S Nijjar, Fraser R Morton, Holger Bang, et al.
The Lancet. Rheumatology|July 27, 2022
Systemic sclerosis in the time of COVID-19Anna-Maria Hoffmann-Vold, Oliver Distler, Cosimo Bruni, et al.
The Lancet. Rheumatology|September 6, 2025
Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trialGabriele De Marco, Elizabeth M A Hensor, Philip S Helliwell, et al.
The Lancet. Rheumatology|March 31, 2021
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort studyJérôme Avouac, Elodie Drumez, Eric Hachulla, et al.
Pageof 46